[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351334-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-351334-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","does-immunotherapy-hold-great-promise-in-endometrial-cancer-care-comprehensive-review-of-emerging-therapeutic-directions","Does immunotherapy hold great promise in endometrial cancer care? - Comprehensive review of emerging therapeutic directions","","Endometrial cancer is a hormone-driven malignancy characterized by global disparities and long-standing endocrine imbalance, especially prolonged unopposed oestrogen exposure. Current care combines surgery, radiotherapy, hormonal therapy and chemotherapy, while the treatment landscape is rapidly shifting toward immunotherapeutic approaches. This review synthesizes evidence on immune checkpoint inhibitors, cancer vaccines targeting tumour-associated antigens, adoptive cellular therapies such as CAR T cells, and bio marker-driven strategies. It also highlights PI3K/AKT/mTOR as a therapeutic target and examines hormone–immune crosstalk in the tumour microenvironment, with emphasis on options relevant to Poland.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/does-immunotherapy-hold-great-promise-in-endometrial-cancer-care-comprehensive-review-of-emerging-therapeutic-directions/351334/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/does-immunotherapy-hold-great-promise-in-endometrial-cancer-care-comprehensive-review-of-emerging-therapeutic-directions/351334.png","ImageObject",300,407,{"name":42,"@type":43},"\tCallum ","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is hormonal dysregulation central to endometrial cancer development and progression?","Question",{"text":63,"@type":64},"Endometrial cancer biology is shaped by endocrine imbalance, especially prolonged exposure to unopposed oestrogen, which supports tumour initiation and progression. Hormone signalling between oestrogen and progesterone also underpins the common use of hormonal therapies.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which immunotherapy approaches are discussed as promising for endometrial cancer care?",{"text":68,"@type":64},"The review covers immune checkpoint inhibitors, cancer vaccines targeting tumour-associated antigens, and adoptive cellular therapies such as CAR T-cell therapy. It also addresses biomarker-driven treatments and rational combination regimens in ongoing clinical trials.",{"name":70,"@type":61,"acceptedAnswer":71},"What additional therapeutic direction is highlighted beyond immunotherapy?",{"text":72,"@type":64},"The review emphasizes the PI3K/AKT/mTOR signalling cascade as a key therapeutic target that may improve endocrine treatment effectiveness. It also stresses the role of crosstalk between hormonal dysregulation and immune mechanisms within the tumour microenvironment.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},351334,1790158607,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},137451211410,"https://ap-avatar.wpscdn.com/avatar/2000bb0a9246f588df?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786362646172706240","TYPE Review  \nPUBLISHED 16 March 2026  \nDOI 10.3389/fimmu.2026.1763091  \nOPEN ACCESS  \nEDITED BY  \nLianCheng Zhu,  \nChina Medical University, China  \nREVIEWED BY  \nKazuhisa Hachisuga, Kyushu University, Japan Mari Uyeda,  \nFundacao Antonio Prudente, Brazil  \n*CORRESPONDENCE  \nMalgorzata Braszka  \n [gosia.braszka@gmail.com](gosia.braszka@gmail.com)  \nRECEIVED 08 December 2025  \nREVISED 16 February 2026  \nACCEPTED 25 February 2026  \nPUBLISHED 16 March 2026  \nCITATION  \nBraszka M, Chowaniec H, Borowczyk M, Dwojak E, Ste˛pien´ M, S´lubowska A, Mielczarek M, Markiewicz H, Ałtyn R, Zielin´ski P, Czerniak J, Adamczak O, Kluk A, Dworacki G and Dobosz P (2026) Does immunotherapy hold great promise in endometrial cancer care? Front. Immunol. 17:1763091 .  \ndoi: 10.3389/fimmu.2026.1763091  \nCOPYRIGHT  \n© 2026 Braszka, Chowaniec, Borowczyk, Dwojak, Ste˛pien´, S´lubowska, Mielczarek, Markiewicz, Ałtyn, Zielin´ski, Czerniak, Adamczak, Kluk, Dworacki and Dobosz. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) .  \nThe use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nDoes immunotherapy hold great promise in endometrial cancer care?  \nMalgorzata Braszka 1*, Hanna Chowaniec 2, Martyna Borowczyk 3, Ewa Dwojak 2,4, Maria Ste˛ pie ´n5,6, Antonina ´Slubowska 7,  \nMagda Mielczarek 8, Hanna Markiewicz 9,10, Rafał Ałtyn11, Paweł Zieli ´nski 2, Joanna Czerniak 2, Oliwier Adamczak 12, Andrzej Kluk 2, Grzegorz Dworacki 2 and Paula Dobosz 2  \n1Cairns Base Hospital, Cairns, QLD, Australia, 2Chair of Pathomorphology and Clinical Immunology, Poznan University of Medical Sciences, Poznan, Poland, 3 Department of Endocrinology, Internal Medicine and Metabolism, Poznan University of Medical Sciences, Poznan, Poland, 4 Department of Pathomorphology, University Clinical Hospital, Poznan, Poland, 5 Universite´ Paris-Saclay, UVSQ, INSERM END-ICAP, Versailles, France, 6 Doctoral School, Medical University of Lublin, Lublin, Poland, 7Cardinal Stefan Wyszynski University of Warsaw, Faculty of Medicine, Collegium Medicum, Department of Biostatistics and Research Methodology, Warsaw, Poland, 8 Department of Genetics, Wrocław University of Environmental and Life Sciences., Wrocław, Poland, 9 Department of Histology and Embryology, Faculty of Medicine, Medical University of Warsaw, Warsaw, Poland, 10 Department of Methodology, Faculty of Medicine, Medical University of Warsaw, Warsaw, Poland, 11 IT Department, Poznan University of Medical Sciences, Poznan, Poland, 12 Poznan University of Medical Sciences, Poznan, Poland  \nEndometrial cancer (EC) is a hormonally driven malignancy with a strikingly uneven global distribution, interestingly occurring far more frequently in developed countries. Central to its pathogenesis is endocrine imbalance, which is most notably due to prolonged exposure to unopposed oestrogen, which fuels tumour initiation and progression. The dynamic interplay between oestrogen and progesterone signalling shapes disease biology and underpins the widespread use of hormonal therapies, particularly in early-stage disease and in patients who are not surgical candidates. Current EC management relies on a multimodal approach, integrating surgery, radiotherapy, hormonal therapy, and chemotherapy. However, the therapeutic landscape is rapidly evolving. Ongoing clinical trials are investigating innovative immunotherapeutic strategies, including bio marker-driven treatments, rational combination regimens, and adoptive cellular therapies. Immune checkpoint inhibitors have already demonstrated clinical beneﬁt in mismatch repair–deﬁcient EC. In parallel, cancer vaccines targeting tumour-associated antigens such as folate-bi","cbCaivW1nWA3LE3w","https://ap.wps.com/l/cbCaivW1nWA3LE3w","pdf",1110495,18,"English","# Introduction - demographics of endometrial cancer\n## Hormonal drivers and endocrine imbalance in disease biology\n## Current multimodal management and evolving treatment landscape\n## Emerging immunotherapeutic strategies\n## Therapeutic targets and tumour microenvironment interactions","[{\"question\":\"Why is hormonal dysregulation central to endometrial cancer development and progression?\",\"answer\":\"Endometrial cancer biology is shaped by endocrine imbalance, especially prolonged exposure to unopposed oestrogen, which supports tumour initiation and progression. Hormone signalling between oestrogen and progesterone also underpins the common use of hormonal therapies.\"},{\"question\":\"Which immunotherapy approaches are discussed as promising for endometrial cancer care?\",\"answer\":\"The review covers immune checkpoint inhibitors, cancer vaccines targeting tumour-associated antigens, and adoptive cellular therapies such as CAR T-cell therapy. It also addresses biomarker-driven treatments and rational combination regimens in ongoing clinical trials.\"},{\"question\":\"What additional therapeutic direction is highlighted beyond immunotherapy?\",\"answer\":\"The review emphasizes the PI3K/AKT/mTOR signalling cascade as a key therapeutic target that may improve endocrine treatment effectiveness. It also stresses the role of crosstalk between hormonal dysregulation and immune mechanisms within the tumour microenvironment.\"}]","Does immunotherapy hold great promise in endometrial cancer care? - Comprehensive review of emerging therapeutic directions | PDF",1790093591,45,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b2fee9426a3d06585f4acd2a674fce23.webp",983,1389,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cd429468e4523bf3f9b76431f399a9c1.webp",982,1388,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/699f02c44625f6b6ace87b8b839ade03.webp",981,1387,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e2f31ca74fb6deeefda25346a0c9c345.webp",980,1385]